tbuckley/cabot-search huggingface dataset:
Evolution of Myocardial Tissue Injury
Authors: Agnes Mayr, Gert Klug, Martin Reindl, Ivan Lechner, Christina Tiller, Magdalena Holzknecht, Mathias Pamminger, Felix Troger, Michael Schocke, Axel Bauer, Sebastian J. Reinstadler, Bernhard Metzler
Journal: JACC. Cardiovascular imaging (2022)
Dual-targeting prodrug nanotheranostics for NIR-Ⅱ fluorescence imaging-guided photo-immunotherapy of glioblastoma
Authors: Fenglin Li, Yi Lai, Jiayi Ye, Madiha Saeed, Yijing Dang, Zhifeng Zou, Fangmin Chen, Wen Zhang, Zhiai Xu
Journal: Acta Pharmaceutica Sinica B (2022)

Glioblastoma (GBM) therapy is severely impaired by the blood-brain barrier (BBB) and invasive tumor growth in the central nervous system. To improve GBM therapy, we herein presented a dual-targeting nanotheranostic for second near-infrared (NIR-II) fluorescence imaging-guided photo-immunotherapy. Firstly, a NIR-Ⅱ fluorophore MRP bearing donor-acceptor-donor (D-A-D) backbone was synthesized. Then, the prodrug nanotheranostics were prepared by self-assembling MRP with a prodrug of JQ1 (JPC) and T7 ligand-modified PEG5k-DSPE. T7 can cross the BBB for tumor-targeted delivery of JPC and MRP. JQ1 could be restored from JPC at the tumor site for suppressing interferon gamma-inducible programmed death ligand 1 expression in the tumor cells. MRP could generate NIR-II fluorescence to navigate 808 nm laser, induce a photothermal effect to trigger in-situ antigen release at the tumor site, and ultimately elicit antitumor immunogenicity. Photo-immunotherapy with JPC and MRP dual-loaded nanoparticles remarkably inhibited GBM tumor growth in vivo. The dual-targeting nanotheranostic might represent a novel nanoplatform for precise photo-immunotherapy of GBM.
Two thousand years after Archimedes, psychologist finds three topics that will simply not yield to the experimental method
Authors: B. Keith Payne, Mahzarin R. Banaji
Journal: Behavioral and Brain Sciences (2022)

Cesario argues that experiments cannot illuminate real group disparities because they leave out factors that operate in ordinary life. But what Cesario calls flaws are, in fact, the point of the experimental method. Of all the topics in science, we have to wonder why racial discrimination would be uniquely unsuited for investigating with experiments. The argument to give up the most powerful scientific method to study one of the hardest problems we confront is laughable.
Progress in bioactive surface coatings on biodegradable Mg alloys: A critical review towards clinical translation
Authors: Navdeep Singh, Uma Batra, Kamal Kumar, Neeraj Ahuja, Anil Mahapatro
Journal: Bioactive Materials (2022)

Mg and its alloys evince strong candidature for biodegradable bone implants, cardiovascular stents, and wound closing devices. However, their rapid degradation rate causes premature implant failure, constraining clinical applications. Bio-functional surface coatings have emerged as the most competent strategy to fulfill the diverse clinical requirements, besides yielding effective corrosion resistance. This article reviews the progress of biodegradable and advanced surface coatings on Mg alloys investigated in recent years, aiming to build up a comprehensive knowledge framework of coating techniques, processing parameters, performance measures in terms of corrosion resistance, adhesion strength, and biocompatibility. Recently developed conversion and deposition type surface coatings are thoroughly discussed by reporting their essential therapeutic responses like osteogenesis, angiogenesis, cytocompatibility, hemocompatibility, anti-bacterial, and controlled drug release towards in-vitro and in-vivo study models. The challenges associated with metallic, ceramic and polymeric coatings along with merits and demerits of various coatings have been illustrated. The use of multilayered hybrid coating comprising a unique combination of organic and inorganic components has been emphasized with future perspectives to obtain diverse bio-functionalities in a facile single coating system for orthopedic implant applications.
Culturally fluent real-world disparities can blind us to bias: Experiments using a cultural lens can help
Authors: Daphna Oyserman, Amabel Youngbin Jeon
Journal: Behavioral and Brain Sciences (2022)

Abstract Culture provides people with rich, detailed, implicit, and explicit knowledge about associations (what goes together) and contingencies (how situations are likely to unfold). These culture-based expectations allow people to get through their days without much systematic reasoning. Experimental designs that unpack these situated effects of culture on thinking, feeling, and doing can advance bias research and direct policy and intervention.
GIMAP6 regulates autophagy, immune competence, and inflammation in mice and humans
Authors: Yikun Yao, Ping Du Jiang, Brittany N. Chao, Deniz Cagdas, Satoshi Kubo, Arasu Balasubramaniyam, Yu Zhang, Bella Shadur, Adeeb NaserEddin, Les R. Folio, Benjamin Schwarz, Eric Bohrnsen, Lixin Zheng, Matthew Lynberg, Simone Gottlieb, Michael A. Leney-Greene, Ann Y. Park, Ilhan Tezcan, Ali Akdogan, Rahsan Gocmen, Sevgen Onder, Avi Rosenberg, Elizabeth J. Soilleux, Errin Johnson, Peter K. Jackson, Janos Demeter, Samuel D. Chauvin, Florian Paul, Matthias Selbach, Haydar Bulut, Menna R. Clatworthy, Zewen K. Tuong, Hanlin Zhang, Benjamin J. Stewart, Catharine M. Bosio, Polina Stepensky, Simon Clare, Sundar Ganesan, John C. Pascall, Oliver Daumke, Geoffrey W. Butcher, Andrew J. McMichael, Anna Katharina Simon, Michael J. Lenardo
Journal: The Journal of Experimental Medicine (2022)

Inborn errors of immunity (IEIs) unveil regulatory pathways of human immunity. We describe a new IEI caused by mutations in the GTPase of the immune-associated protein 6 (GIMAP6) gene in patients with infections, lymphoproliferation, autoimmunity, and multiorgan vasculitis. Patients and Gimap6-/- mice show defects in autophagy, redox regulation, and polyunsaturated fatty acid (PUFA)-containing lipids. We find that GIMAP6 complexes with GABARAPL2 and GIMAP7 to regulate GTPase activity. Also, GIMAP6 is induced by IFN-γ and plays a critical role in antibacterial immunity. Finally, we observed that Gimap6-/- mice died prematurely from microangiopathic glomerulosclerosis most likely due to GIMAP6 deficiency in kidney endothelial cells.
Ukraine War Could Push an Additional 47 Million Into Acute Hunger
Authors: Howard D. Larkin
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer
Authors: Chang-Suk Chae, Tito A. Sandoval, Sung-Min Hwang, Eun Sil Park, Paolo Giovanelli, Deepika Awasthi, Camilla Salvagno, Alexander Emmanuelli, Chen Tan, Vidyanath Chaudhary, Julia Casado, Andrew V. Kossenkov, Minkyung Song, Franck J. Barrat, Kevin Holcomb, E. Alfonso Romero-Sandoval, Dmitriy Zamarin, David Pépin, Alan D. D'Andrea, Anniina Färkkilä, Juan R. Cubillos-Ruiz
Journal: Cancer Discovery (2022)

Abstract Lysophosphatidic acid (LPA) is a bioactive lipid enriched in the tumor microenvironment of immunosuppressive malignancies such as ovarian cancer. Although LPA enhances the tumorigenic attributes of cancer cells, the immunomodulatory activity of this phospholipid messenger remains largely unexplored. Here, we report that LPA operates as a negative regulator of type I interferon (IFN) responses in ovarian cancer. Ablation of the LPA-generating enzyme autotaxin (ATX) in ovarian cancer cells reprogrammed the tumor immune microenvironment, extended host survival, and improved the effects of therapies that elicit protective responses driven by type I IFN. Mechanistically, LPA sensing by dendritic cells triggered PGE2 biosynthesis that suppressed type I IFN signaling via autocrine EP4 engagement. Moreover, we identified an LPA-controlled, immune-derived gene signature associated with poor responses to combined PARP inhibition and PD-1 blockade in patients with ovarian cancer. Controlling LPA production or sensing in tumors may therefore be useful to improve cancer immunotherapies that rely on robust induction of type I IFN. Significance: This study uncovers that ATX–LPA is a central immunosuppressive pathway in the ovarian tumor microenvironment. Ablating this axis sensitizes ovarian cancer hosts to various immunotherapies by unleashing protective type I IFN responses. Understanding the immunoregulatory programs induced by LPA could lead to new biomarkers predicting resistance to immunotherapy in patients with cancer. See related commentary by Conejo-Garcia and Curiel, p. 1841. This article is highlighted in the In This Issue feature, p. 1825
Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
Authors: Randall A. Oyer, Patricia Hurley, Leigh Boehmer, Suanna Steeby Bruinooge, Kathryn Levit, Nadine Barrett, Al Benson, Lea Ann Bernick, Leslie Byatt, Marjory Charlot, Jennie Crews, Kyle DeLeon, Lola Fashoyin-Aje, Elizabeth Garrett-Mayer, Julie R. Gralow, Sybil Green, Carmen E. Guerra, Leila Hamroun, Claudia M. Hardy, Bridgette Hempstead, Sanford Jeames, Mel Mann, Khalid Matin, Worta McCaskill-Stevens, Janette Merrill, Grzegorz S. Nowakowski, Manali I. Patel, Alice Pressman, Amelie G. Ramirez, Juanita Segura, Barbara Segarra-Vasquez, Jen Hanley Williams, James E. Williams, Karen M. Winkfield, Eddy S. Yang, Victoria Zwicker, Lori J. Pierce
Journal: Journal of Clinical Oncology (2022)

A concerted commitment across research stakeholders is necessary to increase equity, diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and participation. Racial and ethnic diversity among trial participants is key to understanding intrinsic and extrinsic factors that may affect patient response to cancer treatments. This ASCO and Association of Community Cancer Centers (ACCC) Research Statement presents specific recommendations and strategies for the research community to improve EDI in cancer clinical trials. There are six overarching recommendations: (1) clinical trials are an integral component of high-quality cancer care, and every person with cancer should have the opportunity to participate; (2) trial sponsors and investigators should design and implement trials with a focus on reducing barriers and enhancing EDI, and work with sites to conduct trials in ways that increase participation of under-represented populations; (3) trial sponsors, researchers, and sites should form long-standing partnerships with patients, patient advocacy groups, and community leaders and groups; (4) anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving EDI; (5) research stakeholders should invest in programs and policies that increase EDI in trials and in the research workforce; and (6) research stakeholders should collect and publish aggregate data on racial and ethnic diversity of trial participants when reporting results of trials, programs, and interventions to increase EDI. The recommendations are intended to serve as a guide for the research community to improve participation rates among people from racial and ethnic minority populations historically under-represented in cancer clinical trials. ASCO and ACCC will work at all levels to advance the recommendations in this publication.
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with <i>NTRK</i> Fusion–Positive Solid Tumors
Authors: George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
Journal: Clinical Cancer Research (2022)

In the earlier version of this article as it was published online on February 10, 2022 (1) and in the printed article, the disclosures of Salvatore Siena and Jeeyun Lee were missing. The HTML and PDF versions of this article were corrected in the online release of the April 1, 2022 issue (2). The publisher regrets the error.
Engineering a biomimetic bone scaffold that can regulate redox homeostasis and promote osteogenesis to repair large bone defects
Authors: Cam-Hoa Mac, Hao-Yu Chan, Yi-Hsuan Lin, Amit Kumar Sharma, Hsiang-Lin Song, Yi-Sheng Chan, Kun-Ju Lin, Yu-Jung Lin, Hsing-Wen Sung
Journal: Biomaterials (2022)
Balloon- vs Self-Expanding Valve Systems for Failed Small Surgical Aortic Valve Bioprostheses
Authors: Josep Rodés-Cabau, Amr E. Abbas, Vicenç Serra, Victoria Vilalta, Luis Nombela-Franco, Ander Regueiro, Karim M. Al-Azizi, Ayman Iskander, Lenard Conradi, Jessica Forcillo, Scott Lilly, Alvaro Calabuig, Eduard Fernandez-Nofrerias, Siamak Mohammadi, Vassili Panagides, Emilie Pelletier-Beaumont, Philippe Pibarot
Journal: Journal of the American College of Cardiology (2022)
Discovery of a Biomarker Signature That Reveals a Molecular Mechanism Underlying Diabetic Kidney Disease via Organ Cross Talk
Authors: I-Wen Wu, Tsung-Hsien Tsai, Chi-Jen Lo, Yi-Ju Chou, Chi-Hsiao Yeh, Mei-Ling Cheng, Chi-Chun Lai, Huey-Kang Sytwu, Ting-Fen Tsai
Journal: Diabetes Care (2022)

Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease, and it creates tremendous medical care costs.Accurate prediction of DKD and its potential molecular implications remain incompletely understood.Here, we apply artificial intelligence (AI) algorithms to build up an interaction model that tackles the complex interconnections between diabetes and chronic kidney disease (CKD) and to identify a biomarker signature that predisposes high-risk type 2 diabetes patients to progression to DKD.The cohort in this study contains 618 subjects, and these can be split into training (557 subjects) and testing (61 subjects) cohorts.Their mean age was 63.8 ± 12.9 years, and they included 287 males (46.4%).The median estimated glomerular filtration rate was 83.0 mL/min/ 1.73 m 2 .Of the subjects, 338 (54.7%) were control subjects, 112 (18.1%) had type 2 diabetes, 73 (11.8%) had nondiabetic CKD, and 95 (15.4%) had DKD (Fig. 1A).The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved
Usefulness of intraductal cholangioscopy biopsy forceps in critical strictures of the biliary anastomosis after liver transplantation
Authors: Belén Martínez-Moreno, Juan Martínez-Sempere, Francisco Ruíz Gómez, Luis Compañy, Carolina Mangas-Sanjuan, Juan Antonio Casellas, José Ramón Aparicio
Journal: Endoscopy (2022)

Anastomotic strictures are a frequent complication after liver transplantation [1]. The key step in endoscopic treatment is getting a guidewire through the stricture. When strictures are critical, an intraductal cholangioscopy (IDC) system (SpyGlass) can help with passage of the guidewire under direct visualization [2]. In very severe strictures, however, this may be insufficient to achieve guidewire passage, even for small caliber guidewires.
Efficacy of App-Based Cognitive Behavioral Therapy for Body Dysmorphic Disorder with Coach Support: Initial Randomized Controlled Clinical Trial
Authors: Sabine Wilhelm, Hilary Weingarden, Jennifer L. Greenberg, Susanne S. Hoeppner, Ivar Snorrason, Emily E. Bernstein, Thomas H. McCoy, Oliver T. Harrison
Journal: Psychotherapy and Psychosomatics (2022)

&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; Body dysmorphic disorder (BDD) is severe, chronic, and undertreated. Apps could substantially improve treatment access. &lt;b&gt;&lt;i&gt;Objective:&lt;/i&gt;&lt;/b&gt; We provide an initial test of the usability and efficacy of coach-supported app-based cognitive behavioral therapy (CBT) for BDD. The Perspectives app covers core treatment components: psychoeducation, cognitive restructuring, exposure with response prevention, mindfulness, attention retraining, and relapse prevention. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; A randomized waitlist-controlled trial was conducted. Adults (&lt;i&gt;N&lt;/i&gt; = 80) with primary BDD were assigned to 12 weeks of Perspectives or waitlist. Coaches promoted engagement and answered questions via in-app messaging and phone calls. BDD severity was measured at baseline, mid-treatment, and end of treatment by blinded independent evaluators (Yale-Brown Obsessive Compulsive Scale Modified for BDD; BDD-YBOCS). Secondary outcomes included BDD-related insight, depression, quality of life, and functioning. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; App uptake and satisfaction were high. In intent-to-treat analyses, Perspectives app-based CBT was associated with significantly lower BDD-YBOCS severity at end of treatment (M [SD]: 16.8 [7.5]) compared to the waitlist (26.7 [6.2]; &lt;i&gt;p&lt;/i&gt; &amp;#x3c; 0.001, &lt;i&gt;d&lt;/i&gt; = 1.44). App-based CBT was associated with greater improvements across all secondary measures, with medium to large effects. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; Perspectives, supported by a bachelor’s-level coach, is an efficacious, scalable treatment for adults with BDD.
Malignant Mesothelioma Mortality in Women — United States, 1999–2020
Authors: Jacek M. Mazurek, David J. Blackley, David N. Weissman
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

Inhalation of asbestos fibers can cause malignant mesothelioma, a rapidly progressing and lethal cancer of the mesothelium, the thin layer of tissues surrounding internal organs in the chest and abdomen. Patients with malignant mesothelioma have a poor prognosis, with a median survival of 1 year from diagnosis. The estimated median interval from initial occupational asbestos exposure to death is 32 years (range = 13-70 years) (1). Occupational asbestos exposure is most often reported in men working in industries such as construction and manufacturing; however, women are also at risk for exposure to asbestos fibers, and limited data exist on longer-term trends in mesothelioma deaths among women. To characterize deaths associated with mesothelioma and temporal trends in mesothelioma mortality among women in the United States, CDC analyzed annual Multiple Cause of Death records from the National Vital Statistics System for 1999-2020, the most recent years for which complete data are available. The annual number of mesothelioma deaths among women increased significantly, from 489 in 1999 to 614 in 2020; however, the age-adjusted death rate per 1 million women declined significantly, from 4.83 in 1999 to 4.15 in 2020. The largest number of deaths was associated with the health care and social assistance industry (89; 15.7%) and homemaker occupation (129; 22.8%). Efforts to limit exposure to asbestos fibers, including among women, need to be maintained.
PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia
Authors: Brittany M. Curtiss, Jake VanCampen, Jommel Macaraeg, Garth L. Kong, Akram Taherinasab, Mitsuhiro Tsuchiya, William M. Yashar, Yiu H. Tsang, Wesley Horton, Daniel J. Coleman, Joseph Estabrook, Theresa A. Lusardi, Gordon B. Mills, Brian J. Druker, Julia E. Maxson, Theodore P. Braun
Journal: Leukemia (2022)
Enzymatic co-crosslinking of star-shaped poly(ethylene glycol) tyramine and hyaluronic acid tyramine conjugates provides elastic biocompatible and biodegradable hydrogels
Authors: Rong Wang, Xiaobin Huang, Bram Zoetebier, Pieter J. Dijkstra, Marcel Karperien
Journal: Bioactive Materials (2022)

A combination of the viscoelastic properties of hyaluronic acid (HA) and the elastic properties of star shaped 8-arm poly(ethylene glycol) (8-arm PEG) was used to design in-situ forming hydrogels. Hydrogels were prepared by the enzymatic crosslinking of a partially tyramine modified 8-arm PEG and a tyramine conjugated HA using horseradish peroxidase in the presence of hydrogen peroxide. Hydrogels of the homopolymer conjugates and mixtures thereof were rapidly formed within seconds under physiological conditions at low polymer and enzyme concentrations. Elastic hydrogels with high gel content (≥95%) and high storage moduli (up to 22.4 kPa) were obtained. An in vitro study in the presence of hyaluronidase (100 U/mL) revealed that with increasing PEG content the degradation time of the hybrid hydrogels increased up to several weeks, whereas hydrogels composed of only hyaluronic acid degraded within 2 weeks. Human mesenchymal stem cells (hMSCs) incorporated in the hybrid hydrogels remained viable as shown by a PrestoBlue and a live-dead assay, confirming the biocompatibility of the constructs. The production of an extracellular matrix by re-differentiation of encapsulated human chondrocytes was followed over a period of 28 days. Gene expression indicated that these highly elastic hydrogels induced an enhanced production of collagen type II. At low PEG-TA/HA-TA ratios a higher expression of SOX 9 and ACAN was observed. These results indicate that by modulating the ratio of PEG/HA, injectable hydrogels can be prepared applicable as scaffolds for tissue regeneration applications.
A roadmap of strategies to support cardiovascular researchers: from policy to practice
Authors: Niamh Chapman, Emma E. Thomas, Joanne T. M. Tan, Sally C. Inglis, Jason H. Y. Wu, Rachel E. Climie, Dean S. Picone, Lauren C. Blekkenhorst, Steven G. Wise, Katrina M. Mirabito Colafella, Anna C. Calkin, Francine Z. Marques
Journal: Nature Reviews Cardiology (2022)
The End of<i>Roe v. Wade</i>
Authors: Mary Ziegler
Journal: The American Journal of Bioethics (2022)

The Supreme Court seems poised to overrule Roe v. Wade and hold that there is no constitutional right to choose abortion. The reversal of Roe seems to run counter to public opinion in the United States-while many favor restrictions, a clear majority do not want Roe reversed and favor access to abortion early in pregnancy. The current Court's apparent willingness to run the risk of political pushback has a complex history. Scholars have long described the Court as a countermajoritarian institution, but in practice, as historians have shown, the Court tends not to stray too far from popular opinion. For a Court bent on reversing Roe and tackling a long list of other divisive topic, concerns about institutional legitimacy no longer appear to be an effective check. A post-Roe Court may be more unplugged from popular opinion, with unpredictable results for the future of the democracy.
Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain
Authors: Maros Ferencik, Thomas Mayrhofer, Michael T Lu, Daniel O Bittner, Hamed Emami, Stefan B Puchner, Nandini M Meyersohn, Alexander V Ivanov, Elizabeth C Adami, Deepak Voora, Geoffrey S Ginsburg, James L Januzzi, Pamela S Douglas, Udo Hoffmann
Journal: JACC. Cardiovascular imaging (2022)